Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | GHSR | Q92847 | 1/20 | 0.40 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4823886 | 0.93 | CTSL (0.43) | CTSLCTSSCYP2C9TSHRCYP2C19 | |
| SCHEMBL4894630 | 0.91 | CTSL (0.42) | CTSLCTSSCYP2C9TSHRCYP2C19 | |
| SCHEMBL4827348 | 0.91 | CTSL (0.41) | CTSLCTSSCYP2C9TSHRCYP2C19 | |
| SCHEMBL4818135 | 0.89 | CHRNA7 (0.42) | CTSLCTSSCYP2C9TSHRCYP2C19 | |
| SCHEMBL4818236 | 0.89 | CHRNA7 (0.42) | CTSLCTSSCYP2C9TSHRCYP2C19 | |
| SCHEMBL8252425 | 0.87 | CNR2 (0.43) | CTSLCTSSCYP2C9TSHRCYP2C19 | |
| SCHEMBL4822019 | 0.86 | CHRNA7 (0.40) | CTSLCTSSCYP2C9TSHRCYP2C19 | |
| SCHEMBL4818266 | 0.85 | CHRNA7 (0.39) | CTSLCTSSCYP2C9TSHRCYP2C19 | |
| SCHEMBL4825000 | 0.85 | F10 (0.42) | CTSLCTSSCYP2C9TSHRCYP2C19 | |
| SCHEMBL4824814 | 0.84 | F10 (0.43) | CTSLCTSSKCNH2GHSRPHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7358373-B2 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358373-B2 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070032484-A1 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC | 2007-02-08 | — | — | US | disclosed |
| US-20070032484-A1 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032484-A1 | Cathepsin K inhibitors | CTSK, CTSS, CTSF | CTSL 12/4885CTSS 2/4885CYP2C9 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.